Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Head and Neck Neoplasms | 71 | 2023 | 3976 | 5.480 |
Why?
|
Thyroid Neoplasms | 39 | 2023 | 1866 | 4.580 |
Why?
|
Thyroid Carcinoma, Anaplastic | 18 | 2023 | 259 | 4.120 |
Why?
|
Mouth Neoplasms | 15 | 2023 | 713 | 3.470 |
Why?
|
Oropharyngeal Neoplasms | 30 | 2022 | 1105 | 3.150 |
Why?
|
Carcinoma, Squamous Cell | 47 | 2023 | 5437 | 3.000 |
Why?
|
Osteoradionecrosis | 9 | 2022 | 123 | 1.920 |
Why?
|
Deglutition Disorders | 17 | 2022 | 447 | 1.740 |
Why?
|
Surgical Oncology | 4 | 2020 | 190 | 1.550 |
Why?
|
Magnetic Resonance Imaging | 23 | 2023 | 7702 | 1.230 |
Why?
|
Pyruvic Acid | 10 | 2021 | 133 | 1.210 |
Why?
|
Coronavirus Infections | 5 | 2020 | 651 | 1.150 |
Why?
|
Pneumonia, Viral | 5 | 2020 | 715 | 1.130 |
Why?
|
Lactic Acid | 5 | 2018 | 305 | 1.080 |
Why?
|
Salivary Gland Neoplasms | 6 | 2018 | 489 | 1.050 |
Why?
|
Radiotherapy, Intensity-Modulated | 15 | 2022 | 2104 | 1.040 |
Why?
|
Mandibular Diseases | 3 | 2021 | 45 | 1.040 |
Why?
|
Mandible | 8 | 2022 | 188 | 1.030 |
Why?
|
ErbB Receptors | 6 | 2015 | 2295 | 1.030 |
Why?
|
Thyroidectomy | 9 | 2020 | 486 | 0.970 |
Why?
|
Carcinoma | 12 | 2022 | 2578 | 0.960 |
Why?
|
Carbon Isotopes | 5 | 2021 | 333 | 0.910 |
Why?
|
Humans | 200 | 2023 | 261506 | 0.910 |
Why?
|
Medical Marijuana | 1 | 2023 | 20 | 0.900 |
Why?
|
Cannabidiol | 1 | 2023 | 42 | 0.880 |
Why?
|
Neck Dissection | 8 | 2022 | 290 | 0.870 |
Why?
|
Xenograft Model Antitumor Assays | 13 | 2021 | 3821 | 0.860 |
Why?
|
Hallucinogens | 1 | 2023 | 48 | 0.850 |
Why?
|
Cannabis | 1 | 2023 | 65 | 0.850 |
Why?
|
Xerostomia | 3 | 2022 | 190 | 0.840 |
Why?
|
Pandemics | 5 | 2020 | 1559 | 0.840 |
Why?
|
Radiopharmaceuticals | 8 | 2019 | 1301 | 0.830 |
Why?
|
MicroRNAs | 5 | 2020 | 2947 | 0.820 |
Why?
|
Antineoplastic Agents | 18 | 2023 | 14289 | 0.790 |
Why?
|
L-Lactate Dehydrogenase | 2 | 2021 | 299 | 0.750 |
Why?
|
Contrast Media | 5 | 2022 | 1472 | 0.750 |
Why?
|
Erythropoietin | 7 | 2016 | 205 | 0.740 |
Why?
|
Neoplasm Staging | 28 | 2023 | 13658 | 0.730 |
Why?
|
Cell Line, Tumor | 26 | 2023 | 14551 | 0.720 |
Why?
|
High-Throughput Screening Assays | 1 | 2021 | 216 | 0.720 |
Why?
|
Image Processing, Computer-Assisted | 10 | 2022 | 1648 | 0.700 |
Why?
|
Laryngeal Neoplasms | 6 | 2019 | 518 | 0.690 |
Why?
|
Male | 105 | 2023 | 123000 | 0.680 |
Why?
|
Receptors, Erythropoietin | 10 | 2016 | 70 | 0.680 |
Why?
|
Deglutition | 7 | 2022 | 171 | 0.680 |
Why?
|
Female | 104 | 2023 | 141928 | 0.670 |
Why?
|
Radiation Injuries | 9 | 2020 | 1411 | 0.660 |
Why?
|
Sentinel Lymph Node Biopsy | 6 | 2023 | 1415 | 0.650 |
Why?
|
Cranial Nerve Diseases | 4 | 2021 | 73 | 0.650 |
Why?
|
Neoplasm Invasiveness | 16 | 2020 | 3981 | 0.640 |
Why?
|
Biomarkers, Tumor | 7 | 2021 | 10331 | 0.610 |
Why?
|
Mice, Nude | 17 | 2021 | 4307 | 0.600 |
Why?
|
Middle Aged | 78 | 2023 | 86204 | 0.600 |
Why?
|
Patient Reported Outcome Measures | 10 | 2022 | 799 | 0.590 |
Why?
|
Aged | 74 | 2022 | 70117 | 0.570 |
Why?
|
Practice Guidelines as Topic | 5 | 2020 | 2403 | 0.570 |
Why?
|
Disease Models, Animal | 7 | 2021 | 7222 | 0.560 |
Why?
|
Cancer Survivors | 8 | 2022 | 650 | 0.550 |
Why?
|
Radiation Tolerance | 4 | 2016 | 629 | 0.540 |
Why?
|
Niacinamide | 2 | 2014 | 421 | 0.540 |
Why?
|
STAT3 Transcription Factor | 6 | 2016 | 1121 | 0.530 |
Why?
|
Sialadenitis | 1 | 2015 | 8 | 0.530 |
Why?
|
Carcinoma, Papillary | 8 | 2015 | 584 | 0.530 |
Why?
|
Technetium Tc 99m Pentetate | 1 | 2015 | 14 | 0.530 |
Why?
|
Patient Care Planning | 2 | 2017 | 297 | 0.520 |
Why?
|
Chemoradiotherapy | 10 | 2021 | 1946 | 0.520 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2021 | 8873 | 0.520 |
Why?
|
Salivary Ducts | 1 | 2015 | 56 | 0.520 |
Why?
|
Mannans | 1 | 2015 | 31 | 0.520 |
Why?
|
Retrospective Studies | 53 | 2023 | 37905 | 0.510 |
Why?
|
Dextrans | 1 | 2015 | 90 | 0.510 |
Why?
|
Gastrostomy | 2 | 2013 | 180 | 0.500 |
Why?
|
Lentivirus | 1 | 2015 | 169 | 0.490 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2015 | 132 | 0.480 |
Why?
|
Virion | 1 | 2015 | 161 | 0.480 |
Why?
|
Phenylurea Compounds | 2 | 2014 | 580 | 0.480 |
Why?
|
Mice | 38 | 2022 | 34495 | 0.470 |
Why?
|
Tumor Suppressor Proteins | 2 | 2020 | 1823 | 0.470 |
Why?
|
Survival Analysis | 17 | 2023 | 9180 | 0.470 |
Why?
|
Lymph Nodes | 6 | 2023 | 2967 | 0.460 |
Why?
|
Tumor Suppressor Protein p53 | 5 | 2020 | 3552 | 0.460 |
Why?
|
Signal Transduction | 18 | 2015 | 11965 | 0.460 |
Why?
|
Organ Sparing Treatments | 3 | 2019 | 277 | 0.450 |
Why?
|
Neoplasm, Residual | 2 | 2018 | 1656 | 0.440 |
Why?
|
Animals | 45 | 2022 | 59536 | 0.440 |
Why?
|
Plasmids | 1 | 2015 | 837 | 0.440 |
Why?
|
Hypopharyngeal Neoplasms | 1 | 2013 | 82 | 0.440 |
Why?
|
Milk Proteins | 6 | 2005 | 116 | 0.430 |
Why?
|
Radiotherapy, Adjuvant | 9 | 2019 | 2231 | 0.430 |
Why?
|
Proto-Oncogene Proteins B-raf | 8 | 2023 | 1283 | 0.430 |
Why?
|
Enteral Nutrition | 4 | 2016 | 316 | 0.430 |
Why?
|
Magnetic Resonance Spectroscopy | 4 | 2016 | 624 | 0.430 |
Why?
|
Prospective Studies | 20 | 2023 | 12873 | 0.420 |
Why?
|
Adult | 55 | 2023 | 77950 | 0.420 |
Why?
|
Tumor Burden | 9 | 2018 | 1987 | 0.420 |
Why?
|
Deoxyglucose | 1 | 2012 | 115 | 0.420 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 2 | 2010 | 60 | 0.410 |
Why?
|
Positron-Emission Tomography | 12 | 2022 | 2173 | 0.410 |
Why?
|
Practice Patterns, Physicians' | 1 | 2020 | 1303 | 0.400 |
Why?
|
Parotid Gland | 2 | 2020 | 112 | 0.400 |
Why?
|
Neoplasm Metastasis | 5 | 2018 | 5112 | 0.390 |
Why?
|
Aged, 80 and over | 37 | 2021 | 29902 | 0.390 |
Why?
|
Alveolar Process | 1 | 2010 | 10 | 0.380 |
Why?
|
Jaw Diseases | 1 | 2010 | 21 | 0.380 |
Why?
|
Neoplasm Recurrence, Local | 14 | 2023 | 10035 | 0.380 |
Why?
|
Molecular Targeted Therapy | 1 | 2021 | 2330 | 0.380 |
Why?
|
Carcinoma, Mucoepidermoid | 2 | 2008 | 137 | 0.370 |
Why?
|
Granuloma, Plasma Cell | 1 | 2010 | 38 | 0.370 |
Why?
|
Thyroid Gland | 4 | 2018 | 355 | 0.370 |
Why?
|
Palate, Hard | 1 | 2009 | 12 | 0.370 |
Why?
|
Receptors, Interleukin | 4 | 2018 | 97 | 0.370 |
Why?
|
Quality of Life | 10 | 2022 | 4532 | 0.370 |
Why?
|
Salivary Glands, Minor | 1 | 2009 | 33 | 0.360 |
Why?
|
STAT Transcription Factors | 1 | 2010 | 79 | 0.360 |
Why?
|
Triage | 3 | 2020 | 252 | 0.360 |
Why?
|
Phenotype | 1 | 2021 | 6295 | 0.360 |
Why?
|
Janus Kinases | 2 | 2013 | 174 | 0.360 |
Why?
|
Protein Kinase Inhibitors | 5 | 2022 | 4757 | 0.360 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 272 | 0.350 |
Why?
|
Disease-Free Survival | 16 | 2020 | 10001 | 0.350 |
Why?
|
DNA, Antisense | 1 | 2009 | 42 | 0.350 |
Why?
|
Simian Acquired Immunodeficiency Syndrome | 2 | 2020 | 110 | 0.340 |
Why?
|
Simian Immunodeficiency Virus | 2 | 2020 | 133 | 0.340 |
Why?
|
Reactive Oxygen Species | 1 | 2014 | 987 | 0.340 |
Why?
|
Video-Assisted Surgery | 1 | 2008 | 28 | 0.330 |
Why?
|
Vocal Cords | 2 | 2018 | 90 | 0.330 |
Why?
|
Radiotherapy Dosage | 11 | 2022 | 3842 | 0.330 |
Why?
|
Combined Modality Therapy | 17 | 2023 | 8865 | 0.330 |
Why?
|
Academic Medical Centers | 4 | 2019 | 672 | 0.330 |
Why?
|
Treatment Outcome | 30 | 2022 | 32848 | 0.320 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2021 | 15862 | 0.310 |
Why?
|
cdc42 GTP-Binding Protein | 1 | 2007 | 42 | 0.310 |
Why?
|
Betacoronavirus | 4 | 2020 | 527 | 0.310 |
Why?
|
Thyroid Nodule | 1 | 2008 | 92 | 0.310 |
Why?
|
Cohort Studies | 16 | 2022 | 9244 | 0.310 |
Why?
|
Protein-Tyrosine Kinases | 10 | 2010 | 1756 | 0.310 |
Why?
|
Survival Rate | 13 | 2021 | 12221 | 0.310 |
Why?
|
Transcription Factors | 3 | 2020 | 5270 | 0.300 |
Why?
|
rhoA GTP-Binding Protein | 1 | 2007 | 79 | 0.300 |
Why?
|
rac1 GTP-Binding Protein | 1 | 2007 | 107 | 0.300 |
Why?
|
Lymphatic Metastasis | 7 | 2022 | 4844 | 0.290 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 4 | 2022 | 2370 | 0.290 |
Why?
|
Neoadjuvant Therapy | 5 | 2023 | 4975 | 0.290 |
Why?
|
Algorithms | 9 | 2022 | 3890 | 0.290 |
Why?
|
Guanine Nucleotide Exchange Factors | 1 | 2007 | 159 | 0.280 |
Why?
|
Robotics | 1 | 2010 | 359 | 0.280 |
Why?
|
Lymphedema | 2 | 2023 | 239 | 0.280 |
Why?
|
Tumor Cells, Cultured | 7 | 2021 | 5395 | 0.280 |
Why?
|
Quinazolines | 1 | 2011 | 923 | 0.270 |
Why?
|
Receptors, Interleukin-2 | 5 | 1996 | 186 | 0.270 |
Why?
|
Neoplasms | 8 | 2017 | 15193 | 0.270 |
Why?
|
Nasopharyngeal Neoplasms | 2 | 2020 | 323 | 0.270 |
Why?
|
Telomerase | 3 | 2019 | 525 | 0.260 |
Why?
|
Robotic Surgical Procedures | 2 | 2022 | 481 | 0.260 |
Why?
|
Piperidines | 1 | 2011 | 1035 | 0.260 |
Why?
|
Blood Vessels | 2 | 2020 | 217 | 0.260 |
Why?
|
Immunity, Innate | 2 | 2020 | 677 | 0.260 |
Why?
|
Proportional Hazards Models | 7 | 2020 | 4988 | 0.260 |
Why?
|
Cross-Sectional Studies | 12 | 2022 | 4314 | 0.260 |
Why?
|
Trans-Activators | 7 | 2005 | 1555 | 0.250 |
Why?
|
Quality Improvement | 3 | 2017 | 851 | 0.250 |
Why?
|
Feasibility Studies | 6 | 2021 | 2292 | 0.250 |
Why?
|
United States | 10 | 2020 | 15433 | 0.250 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2023 | 5178 | 0.240 |
Why?
|
Cisplatin | 6 | 2023 | 2432 | 0.240 |
Why?
|
Carcinoma, Neuroendocrine | 2 | 2023 | 716 | 0.240 |
Why?
|
Patient Selection | 3 | 2020 | 2055 | 0.240 |
Why?
|
Radiation, Ionizing | 2 | 2015 | 187 | 0.240 |
Why?
|
Tongue Neoplasms | 2 | 2020 | 246 | 0.240 |
Why?
|
Statistics, Nonparametric | 3 | 2020 | 980 | 0.230 |
Why?
|
Disease Resistance | 1 | 2023 | 23 | 0.230 |
Why?
|
Survivors | 5 | 2022 | 1031 | 0.230 |
Why?
|
Cancer Care Facilities | 5 | 2020 | 884 | 0.230 |
Why?
|
Lipedema | 1 | 2023 | 2 | 0.230 |
Why?
|
Papillomavirus Infections | 3 | 2021 | 980 | 0.230 |
Why?
|
Receptors, CCR5 | 1 | 2023 | 52 | 0.230 |
Why?
|
Dose-Response Relationship, Radiation | 5 | 2019 | 726 | 0.230 |
Why?
|
Down-Regulation | 3 | 2021 | 2074 | 0.230 |
Why?
|
Fluorodeoxyglucose F18 | 4 | 2017 | 1226 | 0.230 |
Why?
|
Alphapapillomavirus | 2 | 2022 | 171 | 0.230 |
Why?
|
Cell Proliferation | 7 | 2021 | 7226 | 0.220 |
Why?
|
Occupational Health | 2 | 2020 | 95 | 0.220 |
Why?
|
Mutation | 13 | 2022 | 15179 | 0.220 |
Why?
|
Young Adult | 16 | 2020 | 21445 | 0.220 |
Why?
|
Exercise Therapy | 2 | 2017 | 288 | 0.220 |
Why?
|
Proto-Oncogene Proteins | 3 | 2005 | 2488 | 0.220 |
Why?
|
Facial Paralysis | 1 | 2022 | 60 | 0.220 |
Why?
|
Receptors, Cytokine | 2 | 2010 | 176 | 0.210 |
Why?
|
Risk Assessment | 9 | 2023 | 6869 | 0.210 |
Why?
|
Tinnitus | 1 | 2022 | 38 | 0.210 |
Why?
|
Carcinogenicity Tests | 1 | 2021 | 70 | 0.210 |
Why?
|
Biosensing Techniques | 1 | 2002 | 75 | 0.200 |
Why?
|
Tonsillar Neoplasms | 1 | 2022 | 80 | 0.200 |
Why?
|
Oligonucleotides | 2 | 2015 | 227 | 0.200 |
Why?
|
Musculoskeletal Manipulations | 1 | 2021 | 12 | 0.200 |
Why?
|
Radiotherapy, High-Energy | 2 | 2013 | 295 | 0.200 |
Why?
|
Fluorocarbons | 1 | 2022 | 63 | 0.200 |
Why?
|
Antigens, CD | 2 | 1997 | 1385 | 0.200 |
Why?
|
Radiotherapy | 5 | 2017 | 1824 | 0.200 |
Why?
|
STAT5 Transcription Factor | 7 | 2011 | 214 | 0.200 |
Why?
|
Perforator Flap | 1 | 2022 | 93 | 0.200 |
Why?
|
Consensus | 3 | 2020 | 978 | 0.200 |
Why?
|
Voice Disorders | 1 | 2021 | 39 | 0.200 |
Why?
|
Prognosis | 14 | 2021 | 21713 | 0.200 |
Why?
|
Granuloma, Laryngeal | 1 | 2000 | 1 | 0.200 |
Why?
|
Aphonia | 1 | 2000 | 2 | 0.200 |
Why?
|
Parotid Neoplasms | 1 | 2002 | 148 | 0.200 |
Why?
|
Surveys and Questionnaires | 6 | 2021 | 5687 | 0.200 |
Why?
|
Time Factors | 9 | 2020 | 12926 | 0.190 |
Why?
|
Models, Biological | 3 | 2017 | 3254 | 0.190 |
Why?
|
Airway Obstruction | 2 | 2001 | 261 | 0.190 |
Why?
|
Granuloma, Pyogenic | 1 | 2000 | 10 | 0.190 |
Why?
|
Speech Disorders | 1 | 2021 | 91 | 0.190 |
Why?
|
Respiratory Muscles | 2 | 2017 | 27 | 0.190 |
Why?
|
Hearing Loss | 1 | 2022 | 153 | 0.190 |
Why?
|
Laryngectomy | 3 | 2017 | 242 | 0.190 |
Why?
|
Trismus | 1 | 2020 | 24 | 0.190 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2012 | 376 | 0.190 |
Why?
|
Skin Neoplasms | 3 | 2014 | 4654 | 0.190 |
Why?
|
Lymphoscintigraphy | 2 | 2023 | 35 | 0.190 |
Why?
|
Neck | 3 | 2015 | 383 | 0.180 |
Why?
|
Oropharynx | 2 | 2019 | 74 | 0.180 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2023 | 370 | 0.180 |
Why?
|
CD4 Antigens | 1 | 2020 | 170 | 0.180 |
Why?
|
Dissection | 1 | 2020 | 156 | 0.180 |
Why?
|
Muscle Strength | 2 | 2017 | 104 | 0.180 |
Why?
|
Analgesics | 1 | 2023 | 390 | 0.180 |
Why?
|
Appointments and Schedules | 1 | 2020 | 98 | 0.180 |
Why?
|
Pharynx | 2 | 2020 | 153 | 0.180 |
Why?
|
Pharyngeal Muscles | 2 | 2018 | 36 | 0.180 |
Why?
|
Ferrosoferric Oxide | 1 | 2020 | 40 | 0.180 |
Why?
|
Endocrine System Diseases | 1 | 2020 | 83 | 0.180 |
Why?
|
Radiosurgery | 1 | 2009 | 1330 | 0.180 |
Why?
|
Heart | 2 | 2020 | 1223 | 0.180 |
Why?
|
Ferric Compounds | 1 | 2020 | 73 | 0.180 |
Why?
|
Pericardial Effusion | 1 | 2020 | 118 | 0.170 |
Why?
|
Health Care Rationing | 1 | 2020 | 94 | 0.170 |
Why?
|
Quality Indicators, Health Care | 2 | 2015 | 348 | 0.170 |
Why?
|
Enzyme Inhibitors | 2 | 2021 | 1879 | 0.170 |
Why?
|
Feedback, Physiological | 1 | 2020 | 193 | 0.170 |
Why?
|
Adenocarcinoma, Sebaceous | 1 | 2019 | 65 | 0.170 |
Why?
|
DNA-Binding Proteins | 8 | 2005 | 4821 | 0.170 |
Why?
|
Tomography, X-Ray Computed | 8 | 2020 | 7551 | 0.170 |
Why?
|
Apoptosis | 5 | 2021 | 7591 | 0.170 |
Why?
|
Maxillofacial Injuries | 1 | 2019 | 13 | 0.170 |
Why?
|
Cyclobutanes | 1 | 2019 | 36 | 0.170 |
Why?
|
Time-to-Treatment | 2 | 2019 | 292 | 0.170 |
Why?
|
Texas | 9 | 2021 | 6311 | 0.170 |
Why?
|
Carboxylic Acids | 1 | 2019 | 57 | 0.170 |
Why?
|
Clonal Evolution | 1 | 2021 | 253 | 0.170 |
Why?
|
Immunohistochemistry | 6 | 2017 | 7548 | 0.170 |
Why?
|
Sebaceous Gland Neoplasms | 1 | 2019 | 99 | 0.170 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2020 | 518 | 0.160 |
Why?
|
Glottis | 1 | 2019 | 67 | 0.160 |
Why?
|
DNA Copy Number Variations | 3 | 2021 | 1516 | 0.160 |
Why?
|
Sex Distribution | 2 | 2019 | 495 | 0.160 |
Why?
|
Iodine Radioisotopes | 2 | 2022 | 371 | 0.160 |
Why?
|
Communicable Disease Control | 1 | 2020 | 175 | 0.160 |
Why?
|
Optical Imaging | 1 | 2019 | 157 | 0.160 |
Why?
|
Janus Kinase 2 | 4 | 2011 | 679 | 0.160 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2020 | 1033 | 0.160 |
Why?
|
Tertiary Care Centers | 1 | 2020 | 403 | 0.160 |
Why?
|
Age Distribution | 2 | 2019 | 698 | 0.160 |
Why?
|
Tyrosine | 7 | 2005 | 498 | 0.160 |
Why?
|
Reference Values | 1 | 2020 | 1099 | 0.160 |
Why?
|
Adenocarcinoma | 2 | 2023 | 7789 | 0.160 |
Why?
|
Metal Nanoparticles | 1 | 2020 | 164 | 0.160 |
Why?
|
Gene Knockdown Techniques | 1 | 2021 | 1077 | 0.160 |
Why?
|
Respiratory Tract Infections | 1 | 2002 | 437 | 0.160 |
Why?
|
Margins of Excision | 1 | 2019 | 285 | 0.160 |
Why?
|
Tissue Scaffolds | 1 | 2019 | 135 | 0.160 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2021 | 703 | 0.160 |
Why?
|
Respiratory Aspiration | 1 | 2017 | 30 | 0.150 |
Why?
|
Patient Safety | 2 | 2020 | 649 | 0.150 |
Why?
|
Exhalation | 1 | 2017 | 60 | 0.150 |
Why?
|
Surgery, Computer-Assisted | 1 | 2019 | 255 | 0.150 |
Why?
|
Metabolomics | 1 | 2021 | 478 | 0.150 |
Why?
|
Program Evaluation | 1 | 2020 | 597 | 0.150 |
Why?
|
Carbon | 1 | 2018 | 149 | 0.150 |
Why?
|
Proton Therapy | 2 | 2018 | 1577 | 0.150 |
Why?
|
Promoter Regions, Genetic | 3 | 2020 | 3101 | 0.150 |
Why?
|
Wound Healing | 2 | 2020 | 815 | 0.150 |
Why?
|
Radiotherapy, Conformal | 3 | 2019 | 902 | 0.150 |
Why?
|
Platinum Compounds | 1 | 2017 | 131 | 0.150 |
Why?
|
Barium | 1 | 2016 | 26 | 0.140 |
Why?
|
Cough | 1 | 2017 | 116 | 0.140 |
Why?
|
Ultrasonography | 2 | 2022 | 1863 | 0.140 |
Why?
|
RNA, Small Interfering | 2 | 2021 | 2216 | 0.140 |
Why?
|
Receptors, Cell Surface | 2 | 2022 | 862 | 0.140 |
Why?
|
Intubation, Gastrointestinal | 1 | 2016 | 79 | 0.140 |
Why?
|
Tissue Engineering | 1 | 2019 | 269 | 0.140 |
Why?
|
Severe Combined Immunodeficiency | 1 | 1997 | 107 | 0.140 |
Why?
|
Radiation Oncology | 1 | 2021 | 529 | 0.140 |
Why?
|
Skull Base | 1 | 2017 | 199 | 0.140 |
Why?
|
Critical Pathways | 1 | 2017 | 149 | 0.140 |
Why?
|
Naphthols | 1 | 2016 | 25 | 0.140 |
Why?
|
Clinical Protocols | 1 | 2018 | 467 | 0.140 |
Why?
|
Surgical Procedures, Operative | 2 | 2010 | 383 | 0.140 |
Why?
|
X Chromosome | 1 | 1997 | 339 | 0.140 |
Why?
|
Follow-Up Studies | 11 | 2018 | 14889 | 0.140 |
Why?
|
Elective Surgical Procedures | 1 | 2017 | 250 | 0.140 |
Why?
|
Glutaminase | 1 | 2016 | 47 | 0.140 |
Why?
|
mRNA Cleavage and Polyadenylation Factors | 1 | 2016 | 60 | 0.140 |
Why?
|
Transcriptome | 2 | 2023 | 1859 | 0.140 |
Why?
|
Interleukin-4 | 1 | 1996 | 284 | 0.140 |
Why?
|
Carbon Radioisotopes | 1 | 2015 | 116 | 0.130 |
Why?
|
Kaplan-Meier Estimate | 6 | 2018 | 6207 | 0.130 |
Why?
|
Monocarboxylic Acid Transporters | 1 | 2015 | 44 | 0.130 |
Why?
|
Metabolism | 1 | 2015 | 55 | 0.130 |
Why?
|
Copper Radioisotopes | 1 | 2015 | 31 | 0.130 |
Why?
|
Population Surveillance | 1 | 2019 | 627 | 0.130 |
Why?
|
Sulfides | 1 | 2015 | 48 | 0.130 |
Why?
|
Interdisciplinary Communication | 1 | 2017 | 280 | 0.130 |
Why?
|
Feedback, Psychological | 1 | 2015 | 18 | 0.130 |
Why?
|
Mucus | 1 | 2015 | 119 | 0.130 |
Why?
|
Reproducibility of Results | 8 | 2019 | 6009 | 0.130 |
Why?
|
Positron Emission Tomography Computed Tomography | 2 | 2018 | 833 | 0.130 |
Why?
|
Glucose | 2 | 2023 | 1248 | 0.130 |
Why?
|
Symporters | 1 | 2015 | 98 | 0.130 |
Why?
|
Thymidylate Synthase | 2 | 2011 | 53 | 0.130 |
Why?
|
Hematinics | 1 | 2016 | 109 | 0.130 |
Why?
|
Databases, Factual | 3 | 2016 | 2218 | 0.130 |
Why?
|
Inhibitory Concentration 50 | 2 | 2012 | 289 | 0.130 |
Why?
|
Heterografts | 2 | 2014 | 733 | 0.130 |
Why?
|
False Negative Reactions | 1 | 2015 | 275 | 0.120 |
Why?
|
Memory Disorders | 1 | 2017 | 295 | 0.120 |
Why?
|
Esthesioneuroblastoma, Olfactory | 1 | 2015 | 110 | 0.120 |
Why?
|
Carbon-13 Magnetic Resonance Spectroscopy | 1 | 2014 | 13 | 0.120 |
Why?
|
Photons | 1 | 2018 | 507 | 0.120 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2018 | 3890 | 0.120 |
Why?
|
Cell-Free Nucleic Acids | 1 | 2016 | 224 | 0.120 |
Why?
|
Copper | 1 | 2015 | 165 | 0.120 |
Why?
|
Multivariate Analysis | 4 | 2016 | 4298 | 0.120 |
Why?
|
Fluoresceins | 1 | 2014 | 73 | 0.120 |
Why?
|
Membrane Transport Proteins | 1 | 2015 | 244 | 0.120 |
Why?
|
Electron Spin Resonance Spectroscopy | 1 | 2013 | 62 | 0.120 |
Why?
|
Evidence-Based Medicine | 1 | 2019 | 1085 | 0.120 |
Why?
|
Medical Audit | 1 | 2015 | 188 | 0.120 |
Why?
|
Age Factors | 3 | 2018 | 5377 | 0.120 |
Why?
|
Constriction, Pathologic | 1 | 2015 | 310 | 0.120 |
Why?
|
Risk Factors | 9 | 2022 | 17523 | 0.120 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 305 | 0.120 |
Why?
|
Ipilimumab | 1 | 2018 | 710 | 0.120 |
Why?
|
Tumor Microenvironment | 2 | 2021 | 2864 | 0.120 |
Why?
|
Specialties, Surgical | 1 | 2016 | 137 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2013 | 2054 | 0.120 |
Why?
|
Glycolysis | 2 | 2018 | 519 | 0.120 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2018 | 607 | 0.120 |
Why?
|
Phosphorylation | 6 | 2013 | 4804 | 0.120 |
Why?
|
src-Family Kinases | 2 | 2013 | 478 | 0.120 |
Why?
|
Skull Base Neoplasms | 1 | 2017 | 314 | 0.120 |
Why?
|
Lymphocytes | 1 | 2018 | 1234 | 0.110 |
Why?
|
Genomics | 3 | 2021 | 2738 | 0.110 |
Why?
|
Gene Expression Regulation | 2 | 2020 | 4053 | 0.110 |
Why?
|
Lung Neoplasms | 2 | 2020 | 11538 | 0.110 |
Why?
|
Signal-To-Noise Ratio | 3 | 2021 | 117 | 0.110 |
Why?
|
Epigenesis, Genetic | 1 | 2020 | 1399 | 0.110 |
Why?
|
Case-Control Studies | 2 | 2020 | 6100 | 0.110 |
Why?
|
Bone Diseases, Infectious | 1 | 2012 | 12 | 0.110 |
Why?
|
Cell Growth Processes | 1 | 2013 | 342 | 0.110 |
Why?
|
Pharyngeal Neoplasms | 1 | 2013 | 133 | 0.110 |
Why?
|
RNA, Messenger | 5 | 2016 | 6150 | 0.110 |
Why?
|
Biopsy, Needle | 1 | 2017 | 1363 | 0.110 |
Why?
|
Patient Positioning | 1 | 2014 | 195 | 0.110 |
Why?
|
Mesenchymoma | 1 | 2012 | 14 | 0.110 |
Why?
|
Delivery of Health Care | 1 | 2020 | 860 | 0.110 |
Why?
|
Osteomalacia | 1 | 2012 | 36 | 0.110 |
Why?
|
Neoplasms, Connective and Soft Tissue | 1 | 2012 | 19 | 0.110 |
Why?
|
Image Enhancement | 2 | 2016 | 561 | 0.110 |
Why?
|
Green Fluorescent Proteins | 1 | 2015 | 694 | 0.110 |
Why?
|
Transducers | 1 | 2012 | 59 | 0.110 |
Why?
|
Genes, Reporter | 1 | 2015 | 798 | 0.110 |
Why?
|
Surgical Flaps | 3 | 2008 | 927 | 0.110 |
Why?
|
Analysis of Variance | 2 | 2016 | 2307 | 0.110 |
Why?
|
Cognitive Dysfunction | 1 | 2017 | 333 | 0.110 |
Why?
|
Cell Division | 5 | 2012 | 2489 | 0.110 |
Why?
|
Predictive Value of Tests | 3 | 2016 | 4892 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2018 | 2594 | 0.110 |
Why?
|
Blotting, Western | 7 | 2016 | 3536 | 0.110 |
Why?
|
Lacrimal Apparatus Diseases | 1 | 2013 | 137 | 0.110 |
Why?
|
Cetuximab | 4 | 2021 | 472 | 0.110 |
Why?
|
Oxidation-Reduction | 1 | 2014 | 717 | 0.100 |
Why?
|
Radiotherapy, Image-Guided | 1 | 2014 | 304 | 0.100 |
Why?
|
Etodolac | 1 | 2011 | 3 | 0.100 |
Why?
|
Cell Survival | 3 | 2013 | 3045 | 0.100 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 280 | 0.100 |
Why?
|
Suppressor of Cytokine Signaling Proteins | 1 | 2011 | 60 | 0.100 |
Why?
|
Endoscopy | 1 | 2015 | 479 | 0.100 |
Why?
|
Energy Metabolism | 2 | 2016 | 992 | 0.100 |
Why?
|
Biomarkers | 3 | 2023 | 5047 | 0.100 |
Why?
|
Soft Tissue Infections | 1 | 2012 | 102 | 0.100 |
Why?
|
Transcription, Genetic | 1 | 2020 | 3154 | 0.100 |
Why?
|
Whole Body Imaging | 1 | 2012 | 114 | 0.100 |
Why?
|
Bone Neoplasms | 2 | 2016 | 2576 | 0.100 |
Why?
|
Oxidative Stress | 1 | 2018 | 1129 | 0.100 |
Why?
|
Genetic Therapy | 2 | 2010 | 1616 | 0.100 |
Why?
|
Infusions, Intra-Arterial | 1 | 2011 | 171 | 0.100 |
Why?
|
Veterans | 1 | 2022 | 1641 | 0.100 |
Why?
|
Transfection | 3 | 2015 | 2944 | 0.100 |
Why?
|
Cell Hypoxia | 3 | 2011 | 328 | 0.100 |
Why?
|
Proto-Oncogene Proteins pp60(c-src) | 1 | 2011 | 96 | 0.100 |
Why?
|
Nose Neoplasms | 1 | 2013 | 229 | 0.100 |
Why?
|
Kinetics | 5 | 2017 | 2049 | 0.100 |
Why?
|
Salvage Therapy | 2 | 2019 | 2054 | 0.100 |
Why?
|
Janus Kinase 3 | 5 | 1998 | 46 | 0.100 |
Why?
|
Eating | 1 | 2013 | 421 | 0.100 |
Why?
|
Guideline Adherence | 1 | 2015 | 636 | 0.100 |
Why?
|
Confidence Intervals | 2 | 2011 | 756 | 0.100 |
Why?
|
Smoking | 1 | 2020 | 2440 | 0.100 |
Why?
|
Eye Neoplasms | 1 | 2013 | 247 | 0.100 |
Why?
|
Hypoxia-Inducible Factor 1 | 1 | 2011 | 55 | 0.100 |
Why?
|
Quality Assurance, Health Care | 1 | 2015 | 585 | 0.100 |
Why?
|
Taxoids | 2 | 2011 | 967 | 0.100 |
Why?
|
Diagnostic Imaging | 1 | 2019 | 1162 | 0.100 |
Why?
|
Mustard Compounds | 1 | 2010 | 8 | 0.100 |
Why?
|
Diphenylamine | 1 | 2010 | 14 | 0.100 |
Why?
|
Bayes Theorem | 3 | 2021 | 1021 | 0.100 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2011 | 212 | 0.100 |
Why?
|
Lymphocyte Activation | 1 | 1996 | 1688 | 0.100 |
Why?
|
Laser Therapy | 1 | 2015 | 411 | 0.100 |
Why?
|
Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2011 | 157 | 0.100 |
Why?
|
HIV Infections | 1 | 2023 | 2134 | 0.090 |
Why?
|
Radiation-Sensitizing Agents | 2 | 2010 | 363 | 0.090 |
Why?
|
Phenylpropionates | 1 | 2010 | 19 | 0.090 |
Why?
|
Research Design | 1 | 2018 | 1544 | 0.090 |
Why?
|
Flow Cytometry | 2 | 2014 | 3033 | 0.090 |
Why?
|
Enzyme Activation | 4 | 2005 | 1764 | 0.090 |
Why?
|
Adolescent | 8 | 2019 | 31252 | 0.090 |
Why?
|
Nanoparticles | 1 | 2015 | 554 | 0.090 |
Why?
|
HEK293 Cells | 1 | 2015 | 1489 | 0.090 |
Why?
|
Diffusion Magnetic Resonance Imaging | 2 | 2023 | 341 | 0.090 |
Why?
|
Severity of Illness Index | 5 | 2019 | 4320 | 0.090 |
Why?
|
Incidence | 5 | 2021 | 5673 | 0.090 |
Why?
|
Phantoms, Imaging | 4 | 2021 | 1271 | 0.090 |
Why?
|
In Situ Nick-End Labeling | 1 | 2011 | 448 | 0.090 |
Why?
|
RNA, Long Noncoding | 1 | 2016 | 598 | 0.090 |
Why?
|
Maxillary Sinus Neoplasms | 1 | 2011 | 117 | 0.090 |
Why?
|
Binding Sites | 2 | 2013 | 2171 | 0.090 |
Why?
|
Maxilla | 1 | 2010 | 84 | 0.090 |
Why?
|
Anemia | 1 | 2016 | 689 | 0.090 |
Why?
|
Education, Medical, Graduate | 1 | 2016 | 671 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2011 | 4938 | 0.090 |
Why?
|
Fluorouracil | 2 | 2011 | 1944 | 0.090 |
Why?
|
Interleukin-2 | 4 | 1998 | 842 | 0.090 |
Why?
|
Treatment Failure | 3 | 2017 | 1391 | 0.090 |
Why?
|
Radiation Dosage | 3 | 2020 | 1014 | 0.090 |
Why?
|
Sulfonamides | 2 | 2016 | 1823 | 0.090 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2021 | 1724 | 0.090 |
Why?
|
Diagnosis, Differential | 3 | 2012 | 4744 | 0.090 |
Why?
|
Genetic Vectors | 1 | 2015 | 1694 | 0.090 |
Why?
|
Genetic Predisposition to Disease | 2 | 2022 | 5539 | 0.090 |
Why?
|
Epidermal Growth Factor | 1 | 2011 | 423 | 0.090 |
Why?
|
Immunoblotting | 1 | 2011 | 886 | 0.080 |
Why?
|
Pennsylvania | 1 | 2008 | 64 | 0.080 |
Why?
|
Superoxide Dismutase | 1 | 2010 | 266 | 0.080 |
Why?
|
Mouth Floor | 1 | 2008 | 12 | 0.080 |
Why?
|
Mouth | 2 | 2020 | 122 | 0.080 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2021 | 2291 | 0.080 |
Why?
|
Transplantation, Heterologous | 2 | 2011 | 1082 | 0.080 |
Why?
|
Radionuclide Imaging | 2 | 2023 | 660 | 0.080 |
Why?
|
Mitochondria | 1 | 2015 | 1282 | 0.080 |
Why?
|
Base Sequence | 4 | 2011 | 4917 | 0.080 |
Why?
|
Registries | 3 | 2021 | 2170 | 0.080 |
Why?
|
Mandibular Osteotomy | 2 | 2022 | 33 | 0.080 |
Why?
|
Retreatment | 1 | 2009 | 452 | 0.080 |
Why?
|
Rabbits | 2 | 2020 | 957 | 0.080 |
Why?
|
Ischemia | 1 | 2011 | 391 | 0.080 |
Why?
|
Structure-Activity Relationship | 4 | 1998 | 931 | 0.080 |
Why?
|
Surgeons | 1 | 2015 | 519 | 0.080 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2008 | 108 | 0.080 |
Why?
|
Breast Neoplasms | 2 | 2023 | 15694 | 0.080 |
Why?
|
Larynx | 2 | 2020 | 134 | 0.080 |
Why?
|
Disease Progression | 4 | 2015 | 6682 | 0.080 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2011 | 421 | 0.080 |
Why?
|
DNA Damage | 1 | 2015 | 1954 | 0.080 |
Why?
|
GTPase-Activating Proteins | 1 | 2007 | 126 | 0.070 |
Why?
|
Gene Expression Profiling | 3 | 2023 | 5159 | 0.070 |
Why?
|
Ribonuclease III | 1 | 2008 | 182 | 0.070 |
Why?
|
Melanoma | 2 | 2018 | 5317 | 0.070 |
Why?
|
Oral Surgical Procedures | 1 | 2006 | 32 | 0.070 |
Why?
|
Comorbidity | 3 | 2022 | 2352 | 0.070 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2013 | 1546 | 0.070 |
Why?
|
Equipment Design | 3 | 2015 | 1204 | 0.070 |
Why?
|
Lymph Node Excision | 2 | 2018 | 1959 | 0.070 |
Why?
|
HIV-1 | 2 | 2023 | 653 | 0.070 |
Why?
|
Mandibular Neoplasms | 1 | 2006 | 76 | 0.070 |
Why?
|
Colonic Neoplasms | 1 | 2014 | 1390 | 0.070 |
Why?
|
Papillomaviridae | 2 | 2022 | 624 | 0.070 |
Why?
|
Minimally Invasive Surgical Procedures | 1 | 2008 | 500 | 0.070 |
Why?
|
Interleukin-6 | 1 | 2010 | 1038 | 0.070 |
Why?
|
Neoplastic Stem Cells | 1 | 2013 | 1443 | 0.070 |
Why?
|
Tyrphostins | 1 | 2005 | 107 | 0.060 |
Why?
|
Branchioma | 1 | 2004 | 3 | 0.060 |
Why?
|
Earache | 1 | 2004 | 8 | 0.060 |
Why?
|
Benzamides | 1 | 2010 | 1832 | 0.060 |
Why?
|
Otolaryngology | 1 | 2006 | 129 | 0.060 |
Why?
|
Cell Line | 8 | 2004 | 5114 | 0.060 |
Why?
|
Self Report | 2 | 2020 | 756 | 0.060 |
Why?
|
Photochemotherapy | 1 | 2005 | 96 | 0.060 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2010 | 1265 | 0.060 |
Why?
|
Janus Kinase 1 | 4 | 1998 | 121 | 0.060 |
Why?
|
Sensitivity and Specificity | 4 | 2015 | 4971 | 0.060 |
Why?
|
Research | 1 | 2006 | 415 | 0.060 |
Why?
|
Neovascularization, Pathologic | 1 | 2011 | 1547 | 0.060 |
Why?
|
Image Interpretation, Computer-Assisted | 2 | 2019 | 592 | 0.060 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2018 | 665 | 0.060 |
Why?
|
Carboplatin | 2 | 2020 | 823 | 0.060 |
Why?
|
Early Detection of Cancer | 2 | 2022 | 1258 | 0.060 |
Why?
|
Brachytherapy | 1 | 2009 | 977 | 0.060 |
Why?
|
Kelch-Like ECH-Associated Protein 1 | 1 | 2023 | 104 | 0.060 |
Why?
|
Remission Induction | 1 | 2009 | 3569 | 0.050 |
Why?
|
Anticarcinogenic Agents | 1 | 2005 | 362 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 5319 | 0.050 |
Why?
|
Facial Nerve | 1 | 2022 | 64 | 0.050 |
Why?
|
Motion | 2 | 2015 | 193 | 0.050 |
Why?
|
Philadelphia | 1 | 2002 | 38 | 0.050 |
Why?
|
Microbubbles | 1 | 2022 | 14 | 0.050 |
Why?
|
Electronics | 1 | 2002 | 58 | 0.050 |
Why?
|
Ear Canal | 1 | 2002 | 31 | 0.050 |
Why?
|
Radiometry | 2 | 2018 | 980 | 0.050 |
Why?
|
Acoustics | 1 | 2022 | 42 | 0.050 |
Why?
|
Odorants | 1 | 2002 | 73 | 0.050 |
Why?
|
Carcinoma, Basal Cell | 1 | 2005 | 272 | 0.050 |
Why?
|
Antibodies, Monoclonal, Humanized | 4 | 2019 | 3251 | 0.050 |
Why?
|
Imaging, Three-Dimensional | 2 | 2018 | 925 | 0.050 |
Why?
|
Aneuploidy | 1 | 2023 | 369 | 0.050 |
Why?
|
Macromolecular Substances | 3 | 1998 | 293 | 0.050 |
Why?
|
Ear Neoplasms | 1 | 2002 | 59 | 0.050 |
Why?
|
Prevalence | 2 | 2020 | 3260 | 0.050 |
Why?
|
Patient Readmission | 3 | 2015 | 548 | 0.050 |
Why?
|
Choristoma | 1 | 2001 | 85 | 0.050 |
Why?
|
Arteries | 1 | 2022 | 274 | 0.050 |
Why?
|
Neoplasm Transplantation | 2 | 2014 | 1519 | 0.050 |
Why?
|
Pilot Projects | 2 | 2020 | 2803 | 0.050 |
Why?
|
Disease Management | 2 | 2017 | 1052 | 0.050 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2023 | 249 | 0.050 |
Why?
|
Longitudinal Studies | 2 | 2016 | 1945 | 0.050 |
Why?
|
Echo-Planar Imaging | 1 | 2021 | 73 | 0.050 |
Why?
|
Risk | 1 | 2005 | 1972 | 0.050 |
Why?
|
Computational Biology | 2 | 2019 | 1271 | 0.050 |
Why?
|
Thymus Gland | 1 | 2001 | 294 | 0.050 |
Why?
|
Automation | 1 | 2020 | 151 | 0.040 |
Why?
|
Drainage | 1 | 2022 | 416 | 0.040 |
Why?
|
Probability | 1 | 2021 | 866 | 0.040 |
Why?
|
Survival | 1 | 2019 | 177 | 0.040 |
Why?
|
Validation Studies as Topic | 1 | 2019 | 43 | 0.040 |
Why?
|
Surgical Wound Infection | 2 | 2015 | 450 | 0.040 |
Why?
|
Length of Stay | 3 | 2015 | 1900 | 0.040 |
Why?
|
Microfilament Proteins | 1 | 2022 | 487 | 0.040 |
Why?
|
Computer Simulation | 2 | 2017 | 1529 | 0.040 |
Why?
|
Dextran Sulfate | 1 | 2018 | 72 | 0.040 |
Why?
|
International Cooperation | 1 | 2020 | 323 | 0.040 |
Why?
|
STAT1 Transcription Factor | 2 | 1998 | 156 | 0.040 |
Why?
|
Interleukin-9 | 1 | 1998 | 37 | 0.040 |
Why?
|
Oximes | 1 | 2019 | 175 | 0.040 |
Why?
|
Protein Kinases | 1 | 2022 | 874 | 0.040 |
Why?
|
Erythrocytes | 1 | 1999 | 339 | 0.040 |
Why?
|
Precancerous Conditions | 1 | 2005 | 1058 | 0.040 |
Why?
|
Pentose Phosphate Pathway | 1 | 2018 | 69 | 0.040 |
Why?
|
Citric Acid Cycle | 1 | 2018 | 86 | 0.040 |
Why?
|
Liquid Biopsy | 1 | 2018 | 158 | 0.040 |
Why?
|
Fibrosis | 1 | 2021 | 793 | 0.040 |
Why?
|
Erythropoiesis | 1 | 1998 | 74 | 0.040 |
Why?
|
Mutation, Missense | 1 | 2023 | 1152 | 0.040 |
Why?
|
Polymorphism, Genetic | 2 | 2015 | 1450 | 0.040 |
Why?
|
Glossectomy | 2 | 2008 | 40 | 0.040 |
Why?
|
Bacteria | 1 | 2002 | 611 | 0.040 |
Why?
|
Machine Learning | 1 | 2020 | 319 | 0.040 |
Why?
|
Workflow | 1 | 2019 | 275 | 0.040 |
Why?
|
Carotid Arteries | 1 | 2019 | 240 | 0.040 |
Why?
|
Cranial Nerve Neoplasms | 1 | 2017 | 49 | 0.040 |
Why?
|
Incidental Findings | 1 | 2019 | 272 | 0.040 |
Why?
|
Immunoprecipitation | 2 | 2011 | 591 | 0.040 |
Why?
|
Fluoroscopy | 1 | 2018 | 232 | 0.040 |
Why?
|
Endpoint Determination | 1 | 2018 | 176 | 0.040 |
Why?
|
Pyrimidinones | 1 | 2019 | 314 | 0.040 |
Why?
|
Interferon Type I | 1 | 2018 | 250 | 0.040 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 470 | 0.040 |
Why?
|
Time | 1 | 2017 | 178 | 0.040 |
Why?
|
Receptors, Interleukin-7 | 1 | 1997 | 44 | 0.040 |
Why?
|
Survivorship | 1 | 2017 | 109 | 0.040 |
Why?
|
Skin Transplantation | 2 | 2008 | 173 | 0.040 |
Why?
|
Receptors, Interleukin-4 | 1 | 1996 | 22 | 0.040 |
Why?
|
Pyridones | 1 | 2019 | 348 | 0.040 |
Why?
|
Interleukin-17 | 1 | 2018 | 250 | 0.040 |
Why?
|
Cytoplasm | 1 | 1999 | 652 | 0.040 |
Why?
|
Ultraviolet Rays | 1 | 2019 | 575 | 0.040 |
Why?
|
Induction Chemotherapy | 1 | 2020 | 669 | 0.040 |
Why?
|
Datasets as Topic | 1 | 2017 | 181 | 0.040 |
Why?
|
Dimerization | 1 | 1997 | 304 | 0.040 |
Why?
|
Recombinant Fusion Proteins | 3 | 1996 | 1555 | 0.040 |
Why?
|
Chemoradiotherapy, Adjuvant | 1 | 2019 | 565 | 0.040 |
Why?
|
Macaca mulatta | 1 | 2018 | 717 | 0.040 |
Why?
|
Consensus Development Conferences, NIH as Topic | 1 | 2016 | 6 | 0.040 |
Why?
|
Health Status Indicators | 1 | 2017 | 224 | 0.030 |
Why?
|
Insulin Receptor Substrate Proteins | 1 | 1996 | 132 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 447 | 0.030 |
Why?
|
Palate, Soft | 1 | 2016 | 28 | 0.030 |
Why?
|
Analog-Digital Conversion | 1 | 2015 | 5 | 0.030 |
Why?
|
Receptors, Fc | 1 | 1996 | 69 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2016 | 211 | 0.030 |
Why?
|
Area Under Curve | 1 | 2017 | 700 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2017 | 497 | 0.030 |
Why?
|
Cell Polarity | 1 | 1997 | 208 | 0.030 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2017 | 202 | 0.030 |
Why?
|
Drug Industry | 1 | 2016 | 88 | 0.030 |
Why?
|
Enzymes | 1 | 2015 | 64 | 0.030 |
Why?
|
Fatigue | 1 | 2022 | 1239 | 0.030 |
Why?
|
RNA Precursors | 1 | 2016 | 137 | 0.030 |
Why?
|
Acute Disease | 1 | 2000 | 2422 | 0.030 |
Why?
|
Watchful Waiting | 1 | 2017 | 289 | 0.030 |
Why?
|
Regression Analysis | 1 | 2019 | 1546 | 0.030 |
Why?
|
Genetic Linkage | 1 | 1997 | 512 | 0.030 |
Why?
|
HCT116 Cells | 1 | 2016 | 348 | 0.030 |
Why?
|
Academies and Institutes | 1 | 2016 | 95 | 0.030 |
Why?
|
Organs at Risk | 1 | 2018 | 514 | 0.030 |
Why?
|
Biological Transport | 1 | 2016 | 597 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 3639 | 0.030 |
Why?
|
Central Nervous System | 1 | 2017 | 436 | 0.030 |
Why?
|
Phototherapy | 1 | 2015 | 75 | 0.030 |
Why?
|
Blood Component Transfusion | 1 | 2015 | 89 | 0.030 |
Why?
|
Pain, Postoperative | 1 | 2020 | 610 | 0.030 |
Why?
|
Perfusion | 1 | 2016 | 293 | 0.030 |
Why?
|
Platelet Count | 1 | 2015 | 490 | 0.030 |
Why?
|
Hospitals, University | 1 | 2015 | 209 | 0.030 |
Why?
|
Cause of Death | 1 | 2017 | 752 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2015 | 306 | 0.030 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2016 | 566 | 0.030 |
Why?
|
Observer Variation | 1 | 2016 | 671 | 0.030 |
Why?
|
B-Lymphocytes | 2 | 1997 | 1294 | 0.030 |
Why?
|
Propensity Score | 1 | 2016 | 750 | 0.030 |
Why?
|
Orbit Evisceration | 1 | 2013 | 46 | 0.030 |
Why?
|
Imidazoles | 1 | 2019 | 999 | 0.030 |
Why?
|
Protein Conformation | 1 | 1997 | 1258 | 0.030 |
Why?
|
Nasolacrimal Duct | 1 | 2013 | 53 | 0.030 |
Why?
|
Program Development | 1 | 2015 | 261 | 0.030 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 598 | 0.030 |
Why?
|
Antibodies, Monoclonal | 3 | 2011 | 4367 | 0.030 |
Why?
|
Postoperative Care | 1 | 2017 | 739 | 0.030 |
Why?
|
Hypophosphatemia, Familial | 1 | 2012 | 7 | 0.030 |
Why?
|
Logistic Models | 1 | 2020 | 3441 | 0.030 |
Why?
|
SEER Program | 1 | 2016 | 1000 | 0.030 |
Why?
|
Sex Factors | 1 | 2018 | 2139 | 0.030 |
Why?
|
Microsatellite Repeats | 1 | 2014 | 575 | 0.030 |
Why?
|
Chronic Disease | 1 | 2018 | 1819 | 0.030 |
Why?
|
Pancreatic Neoplasms | 1 | 2010 | 5061 | 0.030 |
Why?
|
Alternative Splicing | 1 | 2016 | 584 | 0.030 |
Why?
|
Hyperbaric Oxygenation | 1 | 2012 | 48 | 0.030 |
Why?
|
Decision Making | 1 | 2020 | 1287 | 0.030 |
Why?
|
Mice, Inbred Strains | 1 | 2013 | 521 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2013 | 875 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2014 | 1053 | 0.030 |
Why?
|
Kidney | 1 | 2021 | 2146 | 0.030 |
Why?
|
Psychometrics | 1 | 2016 | 937 | 0.030 |
Why?
|
Medicare | 1 | 2016 | 860 | 0.030 |
Why?
|
Temporal Arteries | 1 | 2011 | 40 | 0.030 |
Why?
|
Molecular Sequence Data | 5 | 1996 | 6089 | 0.030 |
Why?
|
Polyethylene Glycols | 1 | 2015 | 615 | 0.020 |
Why?
|
Equipment Failure Analysis | 1 | 2012 | 329 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2015 | 785 | 0.020 |
Why?
|
Cognition | 1 | 2017 | 968 | 0.020 |
Why?
|
Gene Expression | 2 | 1998 | 3570 | 0.020 |
Why?
|
Neoplasm Grading | 1 | 2015 | 1742 | 0.020 |
Why?
|
Pemetrexed | 1 | 2011 | 102 | 0.020 |
Why?
|
Phosphoproteins | 1 | 1996 | 1152 | 0.020 |
Why?
|
Genes, p53 | 1 | 1995 | 1090 | 0.020 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2011 | 102 | 0.020 |
Why?
|
Glutamates | 1 | 2011 | 130 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2016 | 2588 | 0.020 |
Why?
|
MAP Kinase Kinase 2 | 1 | 2010 | 44 | 0.020 |
Why?
|
Guanine | 1 | 2011 | 151 | 0.020 |
Why?
|
Cells, Cultured | 2 | 1996 | 5637 | 0.020 |
Why?
|
DNA Methylation | 1 | 2020 | 2669 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2020 | 1371 | 0.020 |
Why?
|
Reoperation | 1 | 2015 | 1382 | 0.020 |
Why?
|
Spheroids, Cellular | 1 | 2011 | 222 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2014 | 945 | 0.020 |
Why?
|
Interleukin-1beta | 1 | 2011 | 300 | 0.020 |
Why?
|
Models, Animal | 1 | 2012 | 664 | 0.020 |
Why?
|
Alleles | 1 | 2016 | 2437 | 0.020 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2010 | 160 | 0.020 |
Why?
|
Stromal Cells | 1 | 2013 | 825 | 0.020 |
Why?
|
Dasatinib | 1 | 2013 | 862 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2015 | 2283 | 0.020 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2010 | 209 | 0.020 |
Why?
|
Amino Acid Sequence | 4 | 1996 | 4233 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2011 | 1165 | 0.020 |
Why?
|
Visual Acuity | 1 | 2013 | 873 | 0.020 |
Why?
|
Cyclooxygenase 2 | 1 | 2011 | 483 | 0.020 |
Why?
|
Triazines | 1 | 2010 | 117 | 0.020 |
Why?
|
Adaptation, Physiological | 1 | 2011 | 360 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2015 | 1274 | 0.020 |
Why?
|
Exome | 1 | 2014 | 1239 | 0.020 |
Why?
|
Mass Screening | 1 | 2017 | 1509 | 0.020 |
Why?
|
Thiazoles | 1 | 2013 | 726 | 0.020 |
Why?
|
Anti-Infective Agents | 1 | 2012 | 446 | 0.020 |
Why?
|
Lip | 1 | 2008 | 33 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2010 | 760 | 0.020 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 206 | 0.020 |
Why?
|
Radiography | 1 | 2012 | 1904 | 0.020 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2011 | 1217 | 0.020 |
Why?
|
Liposomes | 1 | 2010 | 684 | 0.020 |
Why?
|
Cytokines | 1 | 1997 | 2809 | 0.020 |
Why?
|
Indoles | 1 | 2013 | 1009 | 0.020 |
Why?
|
Software | 1 | 2014 | 1321 | 0.020 |
Why?
|
Carcinogenesis | 1 | 2013 | 1026 | 0.020 |
Why?
|
Recurrence | 1 | 2015 | 4758 | 0.020 |
Why?
|
Fibula | 1 | 2008 | 146 | 0.020 |
Why?
|
DNA | 1 | 1995 | 2693 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2016 | 2359 | 0.020 |
Why?
|
Bone Plates | 1 | 2006 | 47 | 0.020 |
Why?
|
Organizational Objectives | 1 | 2006 | 61 | 0.020 |
Why?
|
Staff Development | 1 | 2006 | 61 | 0.020 |
Why?
|
Child | 2 | 2023 | 29154 | 0.020 |
Why?
|
Microsurgery | 1 | 2008 | 244 | 0.020 |
Why?
|
Mice, SCID | 1 | 2010 | 1869 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2006 | 208 | 0.020 |
Why?
|
Research Support as Topic | 1 | 2006 | 122 | 0.020 |
Why?
|
Nitric Oxide | 1 | 2010 | 644 | 0.020 |
Why?
|
Phosphotyrosine | 2 | 1995 | 111 | 0.020 |
Why?
|
Personnel Selection | 1 | 2006 | 87 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2015 | 3719 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2010 | 755 | 0.020 |
Why?
|
Laminin | 1 | 2005 | 194 | 0.020 |
Why?
|
Career Choice | 1 | 2006 | 232 | 0.020 |
Why?
|
Mutagenesis, Site-Directed | 2 | 1995 | 611 | 0.020 |
Why?
|
Proteoglycans | 1 | 2005 | 259 | 0.020 |
Why?
|
Pain | 1 | 2012 | 1658 | 0.010 |
Why?
|
Faculty, Medical | 1 | 2006 | 289 | 0.010 |
Why?
|
Drug Combinations | 1 | 2005 | 621 | 0.010 |
Why?
|
Audiometry | 1 | 2002 | 24 | 0.010 |
Why?
|
Tympanoplasty | 1 | 2002 | 5 | 0.010 |
Why?
|
Paclitaxel | 1 | 2009 | 1996 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2013 | 4078 | 0.010 |
Why?
|
Hypoxia | 1 | 2005 | 443 | 0.010 |
Why?
|
Recombinant Proteins | 2 | 1998 | 2927 | 0.010 |
Why?
|
Rats | 1 | 2011 | 6086 | 0.010 |
Why?
|
Hospital Charges | 1 | 2002 | 75 | 0.010 |
Why?
|
Collagen | 1 | 2005 | 752 | 0.010 |
Why?
|
Temporal Bone | 1 | 2002 | 102 | 0.010 |
Why?
|
Curriculum | 1 | 2006 | 860 | 0.010 |
Why?
|
Pyrimidines | 1 | 2013 | 3518 | 0.010 |
Why?
|
Health Resources | 1 | 2002 | 168 | 0.010 |
Why?
|
Societies, Medical | 1 | 2006 | 1335 | 0.010 |
Why?
|
Biopolymers | 1 | 1999 | 38 | 0.010 |
Why?
|
Models, Statistical | 1 | 2005 | 1171 | 0.010 |
Why?
|
Receptors, Interleukin-9 | 1 | 1998 | 3 | 0.010 |
Why?
|
Oligodeoxyribonucleotides | 1 | 1999 | 261 | 0.010 |
Why?
|
Phenylalanine | 1 | 1998 | 142 | 0.010 |
Why?
|
COS Cells | 1 | 1998 | 377 | 0.010 |
Why?
|
Fibrosarcoma | 1 | 1998 | 135 | 0.010 |
Why?
|
Cell Movement | 1 | 2005 | 2466 | 0.010 |
Why?
|
Retroviridae | 1 | 1998 | 332 | 0.010 |
Why?
|
Biopsy | 1 | 2005 | 3443 | 0.010 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 1998 | 212 | 0.010 |
Why?
|
Protein Multimerization | 1 | 1998 | 240 | 0.010 |
Why?
|
Mutagenesis | 1 | 1998 | 483 | 0.010 |
Why?
|
Polymorphism, Single-Stranded Conformational | 1 | 1995 | 176 | 0.010 |
Why?
|
Gene Transfer Techniques | 1 | 1998 | 716 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 1995 | 1213 | 0.010 |
Why?
|
Dexamethasone | 1 | 1998 | 1450 | 0.010 |
Why?
|
In Vitro Techniques | 1 | 1995 | 1618 | 0.010 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 1995 | 661 | 0.010 |
Why?
|
Peptide Fragments | 1 | 1995 | 1271 | 0.010 |
Why?
|
Infant | 1 | 2001 | 13310 | 0.000 |
Why?
|
T-Lymphocytes | 1 | 1995 | 3869 | 0.000 |
Why?
|